Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 15, 1997

View Archived Issues

Company Profile: CombiChem

Novel hypoglycemic thiazolidinedione derivative presented by Kyorin

Discovery of novel, orally active ACAT inhibitor, FR-186054, reported by Fujisawa

E-4010: highly potent and selective PDE V inhibitor from Eisai

Eisai develops novel retinoids as highly potent and selective RXR agonists

New FPP-based inhibitor of protein farnesyltransferase discovered at Banyu

Raloxifene clinical data supports therapeutic utility of novel SERM

Cangene to evaluate Leucotropin in phase III

Long-term asthma therapy options compared in children

Yamanouchi describes development of dual NK1/NK2 antagonist

Total synthesis of aglaiastatin C, a natural antitumor alkaloid

Pediatric rotavirus vaccine approval recommended

Cytoprotective effects of TTC-909 demonstrated in SHR-SP

OPC-14597: a novel D2 antagonist/DA autoreceptor agonist for schizophrenia

Gliatech's ADCON-L recommended for approval

Fujisawa describes preparation of new 5alpha-reductase inhibitor for BPH

Effects of F-1394 on cholesterol esterification/secretion in cultured human intestinal cells

Phase II results reported for Bexxar

TAP acquires North American rights to Meiact

Bupropion: drug of choice for depression in males with erectile dysfunction?

Mitsubishi Chemical expands R&D at home and abroad

Migranal Nasal Spray approved by FDA

Adenovirus-mediated delivery of human tissue kallikrein: novel gene therapy for hypertension

Somatogen: Q1 1998 highlights

Peptimmune acquires option for HIV vaccine-related technology from MGH

Atopy associated with IL-4R mutation; findings support Immunex's development of soluble IL-4R

Alteon and Genentech collaborate on diabetic complications therapy

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 31, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...